Asahi Kasei licenses XIAFLEX Japanese market

Asahi Kasei licenses XIAFLEX for Japanese market

1:13 PM, 25th March 2011
Asahi Kasei licenses XIAFLEX for Japanese market


TOKYO, JAPAN: Asahi Kasei Pharma has concluded a license agreement with US-based Auxilium Pharmaceuticals, under which Asahi Kasei Pharma received exclusive rights to develop and market Auxilium’s XIAFLEX collagenase clostridium histolyticum in Japan.


XIAFLEX is a novel, first-in-class biologic, developed to address unmet medical needs through the provision of a nonsurgical treatment for Dupuytren’s contracture and Peyronie’s disease. By proceeding with the development of XIAFLEX under this agreement in order to obtain regulatory approval in Japan, Asahi Kasei Pharma is further reinforcing its R&D pipeline in its key strategic fields of orthopedics and urology.

(C) WOC News




Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

PetroAlgae partners with Haldor Topsoe for renewable fuels

  Finalizes co-operation agreement with global catalyst and technology company to upgrade PetroAlgae’s biomass to renewable fuels.   ...

Read more
Dynea buys adhesives company in Romania

  HELSINKI, FINLAND: Dynea Chemicals Oy has acquired the total capital stock of S C Rom Re Ro Munteanu S R L, a privately owned Romanian company ...

Read more
Rhodia buys stake in Phoenix Venture Partners

  With a focus to strengthen its innovation potential, Rhodia has acquired an equity interest in the investment fund.   PARIS, FRANCE: Rh ...

Read more
ADM’s new COO, former Dow Chemical Executive VP

  DECATUR, US: Archer Daniels Midland Company said that Juan R Luciano will join the company in the new role of Executive Vice President and Chi ...

Read more
Ube looks to increase sales in South Korea

  TOKYO, JAPAN: Ube Industries Ltd recently said that it has decided to establish a local subsidiary in South Korea, which will serve as a launc ...

Read more
Amyris signs manufacturing deal with Paraíso Bioenergia SA

  This marks the fifth manufacturing deal for Amyris. Under the agreement, Amyris will construct fermentation and separation capacity to produce ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X